Chandra Bhagat Pharma Ltd Stock Price Today (NSE: CBPL)
Fundamental Score
Chandra Bhagat Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Chandra Bhagat Pharma Ltd share price today is ₹30.50, down 4.77% on NSE/BSE as of 30 March 2026. Chandra Bhagat Pharma Ltd (CBPL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹29.20 (Cr). The 52-week high for CBPL share price is ₹61.50 and the 52-week low is ₹29.95. At a P/E ratio of 47.10x, CBPL is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 2.41% and a debt-to-equity ratio of 0.69.
Chandra Bhagat Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Chandra Bhagat Pharma Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Chandra Bhagat Pharma Share Price: A ROCE Efficiency Analysis
The pharmaceutical industry faces a unique challenge: balancing high research and development (R&D) costs with the need for consistent profitability. This analysis examines the financial standing of Chandra Bhagat Pharma Ltd, with a specific focus on its Return on Capital Employed (ROCE). Currently, the Chandra Bhagat Pharma share price stands at ₹42.20000076293945, with a Price-to-Earnings (PE) ratio of 47.1. This high PE suggests market expectations for future growth, but the critical metric demanding closer scrutiny is the ROCE, reported at 6.0%.
ROCE, a key indicator of capital allocation efficiency, reveals how well a company generates profits from its capital base. A ROCE of 6.0% indicates that for every ₹100 invested in the business, Chandra Bhagat Pharma generates ₹6 in earnings. Compared to sector peers, this requires careful consideration. While a direct comparison is difficult without their specific ROCE data, observing companies like
Mankind Pharma Ltd often points to differences in management efficiency and capital allocation. The perception of management quality, for example, might justify a premium valuation for companies like Mankind Pharma, reflected in a potentially different PE ratio.The relatively low ROCE significantly impacts the company's competitive moat. A strong, widening moat is generally supported by high ROCE, indicating efficient capital utilization and pricing power. Conversely, a 6.0% ROCE may suggest challenges in creating or maintaining a strong economic moat, potentially hindering long-term sustainable growth and profitability. This necessitates further investigation into the company's cost structure, pricing strategies, and operational efficiencies. Factors influencing this could include R&D spending yielding marginal returns, inefficient supply chain management, or pricing pressures from generic competition.
It is important to note that this analysis forms part of a larger 80-parameter fundamental audit, verified by Sweta Mishra. The analysis presents an observational view based on publicly available financial data, focusing on the relationship between the Chandra Bhagat Pharma share price, its PE ratio, and particularly its ROCE, and its potential implications for the company's long-term performance. No investment recommendations are implied.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Chandra Bhagat Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CBPL across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Excellent EPS Growth (18.03% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (18.03% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Balanced Promoter Holding (72.19%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
10 factors identified
Below-Average Return on Equity (2.41%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.00%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (0.24%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Premium Valuation Risk (P/E: 47.10x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-33.82%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-60.64%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-1.59% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (1.60x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.61%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Chandra Bhagat Pharma Ltd Financial Statements
Comprehensive financial data for Chandra Bhagat Pharma Ltd including income statement, balance sheet and cash flow
About CBPL (Chandra Bhagat Pharma Ltd)
Chandra Bhagat Pharma Ltd is a dynamic and rapidly expanding pharmaceutical company dedicated to providing high-quality healthcare solutions across a diverse range of therapeutic a...reas. With a steadfast commitment to innovation and patient well-being, CBPL focuses on the development, manufacturing, and commercialization of essential medicines that address unmet medical needs. Our portfolio encompasses a broad spectrum of formulations, from life-saving injectables to convenient oral dosages, ensuring accessibility and ease of administration for healthcare professionals and patients alike. We strive to deliver impactful therapies that improve outcomes and enhance the quality of life for individuals around the world, building a reputation for reliability, integrity, and excellence in the pharmaceutical industry. CBPL is deeply invested in forging strong partnerships with healthcare providers and institutions to ensure seamless delivery of our products and to stay abreast of evolving medical needs. We maintain a robust distribution network that enables us to efficiently reach hospitals, clinics, and pharmacies throughout India and select international markets. Our highly skilled and dedicated team of professionals is driven by a shared vision of making a positive difference in the lives of patients. We are committed to upholding the highest standards of quality and safety in all aspects of our operations, from sourcing raw materials to manufacturing processes and quality control measures. Our unwavering dedication to research and development is at the heart of our growth strategy. CBPL continuously explores opportunities to expand our product pipeline with novel therapies and innovative drug delivery systems. We believe in investing in cutting-edge technologies and fostering a culture of scientific excellence to drive advancements in healthcare. Through strategic collaborations and partnerships, we seek to leverage the expertise of leading researchers and institutions to accelerate the development of groundbreaking solutions that address the most pressing medical challenges of our time, ultimately contributing to a healthier future for all.
Company Details
Key Leadership
CBPL Share Price: Frequently Asked Questions
What is the current share price of Chandra Bhagat Pharma Ltd (CBPL)?
As of 30 Mar 2026, 12:06 pm IST, Chandra Bhagat Pharma Ltd share price is ₹30.50. The CBPL stock has a market capitalisation of ₹29.20 (Cr) on NSE/BSE.
Is CBPL share price Overvalued or Undervalued?
CBPL share price is currently trading at a P/E ratio of 47.10x, compared to the industry average of 31.77x. Based on this relative valuation, the Chandra Bhagat Pharma Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of CBPL share price?
The 52-week high of CBPL share price is ₹61.50 and the 52-week low is ₹29.95. These values are updated daily from NSE/BSE price data.
What factors affect the Chandra Bhagat Pharma Ltd share price?
Key factors influencing CBPL share price include quarterly earnings growth (Sales Growth: -60.64%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Chandra Bhagat Pharma Ltd a good stock for long-term investment?
Chandra Bhagat Pharma Ltd shows a 5-year Profit Growth of 18.03% and an ROE of 2.41%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.69 before investing in CBPL shares.
How does Chandra Bhagat Pharma Ltd compare with its industry peers?
Chandra Bhagat Pharma Ltd competes with major peers in the Pharmaceuticals. Investors should compare CBPL share price P/E of 47.10x and ROE of 2.41% against the industry averages to determine competitive standing.
What is the P/E ratio of CBPL and what does it mean?
CBPL share price has a P/E ratio of 47.10x compared to the industry average of 31.77x. Investors pay ₹47 for every ₹1 of annual earnings.
How is CBPL performing according to Bull Run's analysis?
CBPL has a Bull Run fundamental score of 26.3/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does CBPL belong to?
CBPL operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Chandra Bhagat Pharma Ltd share price.
What is Return on Equity (ROE) and why is it important for CBPL?
CBPL has an ROE of 2.41%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Chandra Bhagat Pharma Ltd generates profits from shareholders capital.
How is CBPL debt-to-equity ratio and what does it indicate?
CBPL has a debt-to-equity ratio of 0.69, which indicates moderate leverage that should be monitored.
What is CBPL dividend yield and is it a good dividend stock?
CBPL offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Chandra Bhagat Pharma Ltd shares.
How has CBPL share price grown over the past 5 years?
CBPL has achieved 5-year growth rates of: Sales Growth -1.59%, Profit Growth 18.03%, and EPS Growth 18.03%.
What is the promoter holding in CBPL and why does it matter?
Promoters hold 72.19% of CBPL shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Chandra Bhagat Pharma Ltd.
What is CBPL market capitalisation category?
CBPL has a market capitalisation of ₹29 crores, placing it in the Small-cap category.
How volatile is CBPL stock?
CBPL has a beta of N/A. A beta > 1 suggests the Chandra Bhagat Pharma Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is CBPL operating profit margin trend?
CBPL has a 5-year average Operating Profit Margin (OPM) of 0.24%, indicating the company's operational efficiency.
How is CBPL quarterly performance?
Recent quarterly performance shows Chandra Bhagat Pharma Ltd YoY Sales Growth of -60.64% and YoY Profit Growth of -33.82%.
What is the institutional holding pattern in CBPL?
CBPL has FII holding of 0.61% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Chandra Bhagat Pharma Ltd stock.